CANbridge Pharmaceuticals Presents Positive Phase I Data for CAN106 at EHA Congress
China-based rare disease firm CANbridge Pharmaceuticals Inc. (HKG: 1228) released the latest data from a...
China-based rare disease firm CANbridge Pharmaceuticals Inc. (HKG: 1228) released the latest data from a...
US-based OnCusp Therapeutics has entered into a licensing agreement with China’s Multitude Therapeutics for the...
Suzhou-based Ascentage Pharma (HKG: 6855) announced the publication of Phase I clinical study results for...
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the first prescription of its third-generation...
Suzhou-based Ascentage Pharma (HKG: 6855) announced the publication of Phase I clinical study results for...
Shenzhen-based META Pharmaceuticals Inc., a developer of immuno-metabolism targeted small molecules, has reportedly raised RMB...
Novartis AG (NYSE: NVS), BeiGene’s partner, revealed in its Q3 2022 earnings report that it...
Germany-based Bayer (ETR: BAYN) has announced a voluntary recall of a specific lot of its...
Novartis disclosed during its Q2 2022 earnings call that the U.S. FDA deemed clinical data...
Genscript Biotech Corporation (HKG: 1548), a leading China-based Contract Development and Manufacturing Organization (CDMO), has...
Innovent Biologics (HKG: 1801), a prominent biotech firm headquartered in Suzhou, China, and Eli Lilly...
Zai Lab Ltd (NASDAQ: ZLAB), a biopharmaceutical company based in China, has received approval from...